---
title: "BRONCUS-B plans to issue a total of 105 million subscription shares at a premium of approximately 1.3%, raising a net amount of about HKD 327 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260612262.md"
description: "BRONCUS-B plans to issue 105 million subscription shares at a price of HKD 3.11 per share, expecting to raise approximately HKD 327 million in net proceeds, with the subscription price representing a premium of about 1.3% over the market closing price. This issuance will account for approximately 16.60% of the company's issued share capital, and the proceeds will be used for potential acquisitions in the medical device industry to expand the product portfolio"
datetime: "2025-10-10T11:08:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260612262.md)
  - [en](https://longbridge.com/en/news/260612262.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260612262.md)
---

# BRONCUS-B plans to issue a total of 105 million subscription shares at a premium of approximately 1.3%, raising a net amount of about HKD 327 million

According to the announcement from BRONCUS-B (02216), on October 10, 2025, the company entered into subscription agreements with various subscribers, under which the company conditionally agreed to allocate and issue a total of 105 million subscription shares, and the subscribers conditionally agreed to subscribe for the shares at a subscription price of HKD 3.11 per share.

The total number of 105 million subscription shares to be allocated and issued under the subscription matters accounts for approximately 16.60% of the company's issued share capital after the issuance of subscription shares (assuming no changes in the company's issued share capital from the date of this announcement until completion, except for those arising from the subscription matters). The subscription price of HKD 3.11 per subscription share represents a premium of approximately 1.3% over the closing price of HKD 3.07 per share reported on the Stock Exchange on October 10, 2025. The subscription shares will be issued under the general mandate.

The net proceeds from the subscription matters (after deducting expenses) are estimated to be approximately HKD 327 million, equivalent to a net issue price of approximately HKD 3.106 per subscription share. The net proceeds from the subscription matters are intended to be used to fund potential acquisitions in the medical device industry to continuously expand the product portfolio

### Related Stocks

- [02216.HK](https://longbridge.com/en/quote/02216.HK.md)

## Related News & Research

- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [13:41 ETUT Haslam Marks Decade in Major International Ranking's Top Five U.S. Public Schools](https://longbridge.com/en/news/286804132.md)
- [Sparebanken Øst Buys Back Equity Certificates for Employee Savings Scheme](https://longbridge.com/en/news/286813438.md)
- [Release according to article 135 section 2 BörseG](https://longbridge.com/en/news/286754366.md)
- [05:54 ETTermHub™ Launches New Managed FHIR Offering for SDOs](https://longbridge.com/en/news/287042225.md)